Claim: GSK to sell two vaccines in $1.1 billion deal to focus on newer treatments.
Verdict: SUPPORTS

Retrieved passages:
title: GlaxoSmithKline
text: neurodegenerative diseases. Andrew Witty became the chief executive officer in 2008. Witty joined Glaxo in 1985 and had been president of GSK's Pharmaceuticals Europe since 2003. In 2009 GSK acquired Stiefel Laboratories, then the world's largest independent dermatology drug company, for US$3.6bn. In November the FDA approved GSK's vaccine for 2009 H1N1 influenza protection, manufactured by the company's ID Biomedical Corp in Canada. Also in November 2009 GSK formed a joint venture with Pfizer to create ViiV Healthcare, which specializes in HIV research. In 2010 the company acquired Laboratorios Phoenix, an Argentine pharmaceutical company, for US$253m, and the UK-based sports

title: GlaxoSmithKline
text: Human Genome Sciences (HGS) for $3 billion; the companies had collaborated on developing the lupus drug Belimumab (Benlysta), albiglutide for type 2 diabetes, and darapladib for atherosclerosis. In March 2014, GSK paid $1 billion to raise its stake in its Indian pharmaceutical unit, GlaxoSmithKline Pharmaceuticals, to 75 percent as part of a move to focus on emerging markets. In April 2014 Novartis and Glaxo agreed on more than $20 billion in deals, with Novartis selling its vaccine business to GSK and buying GSK's cancer business. In February 2015 GSK announced that it would acquire GlycoVaxyn, a Swiss pharmaceutical company, for

title: Novartis
text: million in the first half of 2013 after a $250 million loss for all 2012... Vaccine revenue was $1.4 billion in 2012 and has been forecast to more than double to $3.14 billion by 2018.". In 2014, Novartis announced its intention of selling the Vaccines Division to CSL Limited for $275 million. This sale was completed in late 2015 and the division was integrated into CSL's BioCSL operation with the combined entity trading as Seqirus Consumer: Novartis is not a leader in the over-the-counter or animal health segments; its leading OTC brands are Excedrin and Theraflu, but sales have been

title: GlaxoSmithKline
text: conferred approximately 50% protection from clinical Plasmodium falciparum disease in children aged 5-17 months, and approximately 30% protection in children aged 6-12 weeks when administered in conjunction with Expanded Program for Immunization (EPI) vaccines." In 2014 Glaxo said it had spent more than $350 million and expected to spend an additional $260 million before seeking regulatory approval. A second generation malaria vaccine is being evaluated in Phase 2 clinical trials. GSK's consumer healthcare division, which earned £5.2 billion in 2013, sells oral healthcare, including Aquafresh, Maclean's and Sensodyne toothpastes; and drinks such as Horlicks, Boost and a chocolate-flavoured malt drink

title: GlaxoSmithKline
text: nutrition company Maxinutrition for £162 million (US$256 million). In 2011, in a $660-million deal, Prestige Brands Holdings took over 17 GSK brands with sales of $210 million, including BC Powder, Beano, Ecotrin, Fiber Choice, Goody's Powder, Sominex and Tagamet. In 2012 the company announced that it would invest £500 million in manufacturing facilities in Ulverston, northern England, designating it as the site for a previously announced biotech plant. In May that year it acquired CellZome, a German biotech company, for US$98 million, and in June worldwide rights to alitretinoin (Toctino), an eczema drug, for $302 million. In 2013 GSK acquired

title: GlaxoSmithKline
text: Consumer Healthcare business for $3.8 billion (£2.98 billion). Unilever will pay the majority of the deal in cash, with the remaining being paid in shares in its Ondian operation, Hindustan Unilever Limited. Upon completion, GSK will then own around 5.7% of Hindustan Unilever Limited, selling those shares in a number of tranches. The same day, the company also announced it would acquire oncology specialist, Tesaro, for $5.1 billion. The deal will give GSK control of ovarian cancer treatment, Zejula - a member of the class of poly ADP ribose polymerase (PARP) inhibitors. In March 2018, GSK announced that it has

title: GlaxoSmithKline
text: to out-license or start new companies around drug candidates that it did not intend to develop further. As of 2003, SR One tended to invest only if the company aligned with GSK's business. GSK manufactures products for major disease areas such as asthma, cancer, infections, diabetes and mental health. Its biggest-selling products in 2013 were Advair, Avodart, Flovent, Augmentin, Lovaza, and Lamictal; its drugs and vaccines earned £21.3 billion that year. Other top-selling products include its asthma/COPD inhalers Advair, Ventolin, and Flovent; its diphtheria/tetanus/pertussis vaccine Infanrix and its hepatitis B vaccine; the epilepsy drug Lamictal, and the antibacterial Augmentin. Medicines

title: GlaxoSmithKline
text: reached an agreement with Novartis to acquire Novartis’ 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion). This acquisition is consistent with the notion prevalent by July 2018 that the company was seriously considering a breakup that would spin-off the company's Consumer division. In December 2018, GSK announced that it, along with Pfizer, had reached an agreement to merge and combine their consumer healthcare divisions into a single entity. The combined entity would have sales of around £9.8 billon ($12.7 billion), with GSK maintaining a 68% controlling stake in the joint venture. Pfizer would own the

title: Novartis
text: reported that Novartis had acquired a 15% stake in Gamida Cell for $35 million, with the option to purchase the whole company for approximately $165 million. In October 2014, Novartis announced its intention to sell its influenza vaccine business (inclusive of its development pipeline), subject to regulatory approval, to CSL for $275 million. In March 2015, the company announced BioPharma had completed its acquisition of two Phase III cancer-drug candidates; the MEK inhibitor binimetinib (MEK 162) and the BRAF inhibitor encorafenib (LGX818), for $85 million. Further, the company sold its RNAi portfolio to Arrowhead Research for $10 million and $25

title: Baxter International
text: public company that showed on trading boards as of July 1, 2015. In July 2014, Baxter announced that it was exiting the vaccines business—divesting its commercial vaccine portfolio to Pfizer (with the sale expected to close by the end of the year) and exploring options for its vaccines R&D program, including influenza. In October 2015, José E. Almeida was named chairman and chief executive officer. In January 2016 Shire PLC agreed to acquire Baxalta for $32 billion. In December 2016, Baxter announced it would acquire Claris Lifesciences injectables subsidiary, Claris Injectables, for $625 million. During the tenure of Vernon Loucks,

title: GlaxoSmithKline
text: $190 million, and in June that year that it would sell two meningitis drugs to Pfizer, Nimenrix and Mencevax for around $130 million. Philip Hampton, at that time chair of the Royal Bank of Scotland, became GSK chairman in September 2015. In September 2016, the company announced that Witty would be succeeded as CEO by Emma Walmsley in March 2017; Walmsley was a management professional originally from Lancashire with a background in marketing. In December 2017, Reuters reported that Glaxo had increased its stake in its Saudi Arabian unit to 75% (from 49%) taking over control from its Saudi partner

title: GlaxoSmithKline
text: billion in 2013, include Sensodyne and Aquafresh toothpaste, the malted-milk drink Horlicks, Abreva for cold sores, Breathe Right nasal strips, Nicoderm and Nicorette nicotine replacements, and Night Nurse, a cold remedy. The company developed the first malaria vaccine, RTS,S, which it said in 2014 it would make available for five percent above cost. Legacy products developed at GSK include several listed in the World Health Organization Model List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine and zidovudine. In 2012 GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data, and kickbacks to physicians in

title: Novartis
text: cool air in at the lower levels and vents warmer air. In January 2009, the United States Department of Health and Human Services awarded Novartis a $486 million contract for construction of the first US plant to produce cell-based influenza vaccine, to be located in Holly Springs, North Carolina. The stated goal of this program is the capability of producing 150,000,000 doses of pandemic vaccine within six months of declaring a flu pandemic. In April 2014, Novartis divested its consumer health section with $3,5 billion worth of assets into a new joint venture with GlaxoSmithkline, named GSK Consumer Healthcare, of

title: Agenus
text: Kettering Cancer Center, Jedd Wolchok, is recognized as one of immuno-oncology’s leading pioneers. GlaxoSmithKline (GSK): March 2012, GSK paid Agenus $9 million to include additional rights to the two firms’ agreement around Agenus’ QS-21 Stimulon® adjuvant. The deal amended license and manufacturing terms. It also included royalty payments to Agenus for an undisclosed indication upon commercialization of a vaccine. Checkpoint Modulators (CPMs) interfere with cancers’ ability to “hijack” natural immune defense systems. To protect the body against disease, but without attacking healthy cells, the immune system uses multiple “checkpoint” systems. Some checkpoints stimulate immune responses while others inhibit them. Cancer

title: GlaxoSmithKline
text: sold in India. GSK also previously owned the Lucozade and Ribena brands of soft drinks, but they were sold in 2013 to Suntory for £1.35bn. Other products include Abreva to treat cold sores; Night Nurse, a cold remedy; Breathe Right nasal strips; and Nicoderm and Nicorette nicotine replacements. In March 2014 it recalled Alli, an over-the-counter weight-loss drug, in the United States and Puerto Rico because of possible tampering, following customer complaints. As of 2013 GSK had offices in over 115 countries and employed over 99,000 people, 12,500 in R&D. The company's single largest market is the United States. Its

title: Garo H. Armen
text: by the results from animal testing; the vaccine cured 80% of mice in the early stages of cancer with virtually no side effects. By February 2000, Antigenics went public at $18 a share, raising $72.5 million. A few months later the U.S. Food and Drug Administration (FDA) agreed to review the vaccine on an accelerated schedule when the company filed for approval, and Antigenics began recruiting 728 patients with kidney cancer for the phase 3 trial, the largest study conducted in the world. Ultimately, 118 cancer centers participated in the trial, 63 of them outside the U.S.. The largest group

title: GlaxoSmithKline
text: remaining 32% shareholding. The deal builds on an earlier 2018 deal where GSK bought out Novartis' stake in the GSK-Novartis consumer healthcare joint business. The culmination of the Consumer Healthcare string of deals will result in GSK splitting into two separate, via a demerger and subsequent listing of the joint venture, creating two publicly traded companies, one focussing on pharmaceuticals and research & development, the other on consumer healthcare. SR One was established in 1985 by SmithKline Beecham to invest in new biotechnology companies and continued operating after GSK was formed; by 2003 GSK had formed another subsidiary, GSK Ventures,

title: Eli Lilly and Company
text: of Boehringer Ingelheim) US feline, canine and rabies vaccines portfolio. In March 2017, the company acquired CoLucid Pharmaceuticals for $960 million, specifically gaining the late clinical-stage migraine therapy candidate, lasmiditan. In May 2018, the company acquired Armo Biosciences for $1.6 billion. Days later the company announced it would acquire Aurora kinase A inhibitor developer - AurKa Pharma - and control over the lead compound, AK-01, for up to $575 million. The following is an illustration of the company's major mergers, acquisitions and historical predecessors: Eli Lilly and Company has a long history of collaboration with research scientists. In 1886 Ernest

title: Julie Gerberding
text: delegate in the World Economic Forum, Gerberding recently received the Surgeon General’s Medallion for actions of exceptional achievement to the cause of public health and medicine. For her contributions to the health field,Accordia Global Health Foundation honored Dr. Gerberding with the Global Health Leadership Award in 2008. In late 2009, Gerberding became president of Merck's vaccines division. Gerberding sold 38,368 shares of her Merck stock on the open market in a transaction dated May 8, 2015. The stock was sold at an average price of $60.99, for a total transaction of $2,340,064.32. Following the sale, the executive vice president now

title: Johnson & Johnson
text: J&J acquired Crucell for $2.4 billion and will operate as the centre for vaccines, within the wider Johnson & Johnson pharmaceuticals group. In November 2015, Biosense Webster, Inc. acquired Coherex, Medical Inc. expanding the companies range of treatment options for patients with atrial fibrillation. In March 2018, the company announced that LifeScan, Inc. would be sold off to Platinum Equity for around $2.1 billion In September of the same year Johnson & Johnson Medical GmbH acquired Emerging Implant Technologies GmbH, manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery. For the fiscal year 2017, Johnson & Johnson reported earnings